Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) EBT (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed EBT for 16 consecutive years, with $56.8 million as the latest value for Q4 2025.

  • Quarterly EBT rose 244.85% to $56.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.0 million through Dec 2025, up 6212.95% year-over-year, with the annual reading at $159.0 million for FY2025, 6212.95% up from the prior year.
  • EBT hit $56.8 million in Q4 2025 for Ligand Pharmaceuticals, down from $141.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $141.1 million in Q3 2025 to a low of -$65.4 million in Q2 2024.
  • Historically, EBT has averaged $16.7 million across 5 years, with a median of $11.8 million in 2022.
  • Biggest five-year swings in EBT: crashed 2162.13% in 2024 and later skyrocketed 2326.49% in 2025.
  • Year by year, EBT stood at $17.9 million in 2021, then skyrocketed by 35.0% to $24.1 million in 2022, then dropped by 29.18% to $17.1 million in 2023, then tumbled by 329.28% to -$39.2 million in 2024, then surged by 244.85% to $56.8 million in 2025.
  • Business Quant data shows EBT for LGNDZ at $56.8 million in Q4 2025, $141.1 million in Q3 2025, and $11.2 million in Q2 2025.